Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: Patient exit interviews
Anthony L, Horsch D, Ervin C, Kulke M, Pavel M, Bergsland E, Caplin M, Oberg K, Warner R, Kunz P, Metz D, Pasieka J, Pavlakis N, DiBenedetti D, Haydysch E, Yang Q, Jackson S, Arnold K, Law L, Lapuerta P. Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: Patient exit interviews. Endocrine Abstracts 2016 DOI: 10.1530/endoabs.46.p11.Peer-Reviewed Original ResearchPatient exit interviewsTelotristat etiprateCarcinoid syndromeTreatment benefitExit interviewsPatientsSyndrome